Item 1.01 Entry into a Material Definitive Agreement.
On January 29, 2020 Cocrystal Pharma, Inc. (the "Company") and A.G.P./Alliance
Global Partners amended its Equity Distribution Agreement, dated as of July 19,
2018 (the "Agreement") to reduce the amount to be raised under the Agreement
from $6,000,000 to $551,576 (inclusive of the $351,576 which has been raised to
date).
The Company's shares of common stock are being offered and sold pursuant to a
base prospectus, dated October 10, 2017, as supplemented by an amended and
restated prospectus supplement dated October 30, 2019, in each case filed with
the Securities and Exchange Commission (the "Commission") as part of the
Company's effective Registration Statement on Form S-3 (File No. 333-220632)
(the "Registration Statement"), which was initially filed with the Commission on
September 26, 2017 and declared effective on October 10, 2017. Interested
investors should read the Registration Statement, the base prospectus and the
prospectus supplement and all documents incorporated therein by reference.
This Current Report on Form 8-K does not constitute an offer to sell or a
solicitation of an offer to buy any securities. The Registration Statement
relating to these securities has been filed with the Commission and is
effective. Copies of the prospectus supplement and base prospectus relating to
the offering may be obtained when available by contacting A.G.P./Alliance Global
Partners, Attention: Thomas Higgins, by calling 212-624-2060, or by visiting
EDGAR on the Commission's website at www.sec.gov.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit Description
1.1 Amendment to the Amended and Restated Equity Distribution Agreement,
dated October 2, 2019© Edgar Online, source Glimpses
COCRYSTAL PHARMA, INC. 
